转移性年轻发病与平均发病胆瘤的生存分析:基于人口的研究
Antoine Jeri-Yabar1, Liliana Vittini-Hernandez1, Brenda Salazar-Linares2
1Department of Medicine, Icahn School of Medicine at Mount Sinai Morningside/West, New York, USA.
Asian Pacific journal of cancer prevention : APJCP
|May 29, 2025
概括
年轻发作的胆管癌 (YOCC) 呈现出不同的转移模式,更多的骨和肺部扩散. 转移性YOCC (mYOCC) 患者的生存率比老年人更好.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 流行病学 流行病学
背景情况:
- 年轻发生胆管癌 (YOCC) 的发病率不断上升.
- 转移性YOCC (mYOCC) 的不清楚生存结果和转移性模式与转移性平均发作胆管癌 (mAOCC) 相比.
研究的目的:
- 评估mYOCC与mAOCC的生存结果,转移模式和预后因素.
- 在mYOCC和mAOCC患者之间比较临床特征和治疗方式.
主要方法:
- 使用SEER数据库 (2018-2021) 进行回顾性队列研究.
- 将患者分层分为mYOCC (<50岁) 和mAOCC (≥50岁).
- 分析了使用卡普兰-梅尔和考克斯模型的临床数据,转移部位,治疗和生存率.
主要成果:
- mYOCC (1601名转移性胆管癌患者中的9.99%) 呈现出更多的骨和肺转移.
- mYOCC显示出多个转移部位的更高患病率,包括骨肝肺结合.
- mYOCC的平均存活时间为12个月,而mAOCC的平均存活时间为9个月,死亡风险较低 (aHR=0.74).
结论:
- mYOCC表现出明显的转移模式和比mAOCC更好的生存结果.
- 对于mYOCC,需要特定于年龄的诊断和治疗策略.
- 对生物机制和生存差异的进一步研究是有必要的.
相关概念视频
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Comparing the Survival Analysis of Two or More Groups
303
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
303
Actuarial Approach
140
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
140
Kaplan-Meier Approach
281
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
281
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K


